Sagimet Biosciences, Inc. Class A's total assets for Q2 2025 were $137.41M, a decrease of -6.00% from the previous quarter. SGMT total liabilities were $7.25M for the fiscal quarter, a 0.93% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.